The U.S. Justice Department has leveled allegations against Regeneron Pharmaceuticals (NASDAQ:REGN), accusing the company of manipulating Medicare’s drug-pricing system for its macular degeneration drug, Eylea (aflibercept).  In a federal court complaint filed in Boston, the department claims that Regeneron inflated the average sales price of Eylea, a move that significantly impacted Medicare expenses. According to the lawsuit, Reuters highlighted that Regeneron purportedly failed to disclose substantial payments to drug distributors to subsidize Eylea’s purchases.  These payments ensured that distributors accepted credit card payments for the drug while offering lower prices to physicians and retina practices. Related: Median Drug Prices For ...